# psoriasis - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 47696
- Completion tokens: 16175
- Reasoning tokens: 0
- Total tokens: 63871
- API requests reported: 3
- Elapsed seconds: 146.98
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: OpenAI

---
## 1. Overall biological interpretation

The 100-gene signature is highly asymmetric: **90 genes are upregulated and 10 are downregulated**, and all 100 have **FDR ≤ 0.01**. The dominant signal is therefore a coordinated lesional-skin state rather than a balanced set of isolated changes. Representative effects include **IL36A (log2FC 11.37, FDR 1.65×10⁻⁹⁸)**, **DEFB4A (11.18, 2.18×10⁻⁶⁹)**, **DEFB4B (11.03, 3.70×10⁻⁷¹)**, **S100A7A (9.83, 9.25×10⁻⁶³)**, **PI3 (9.24, 1.53×10⁻⁶⁹)**, and **SERPINB4 (9.12, 6.68×10⁻⁶⁶)**.

Collectively, the results describe a psoriasis lesion characterized by:

- Strong **keratinocyte inflammatory activation**, particularly an IL-36/IL-20-family and IL-17-associated epithelial response.
- Marked induction of **antimicrobial and barrier-defense genes**.
- **Cornified-envelope remodeling and epidermal hyperplasia**, supported by SPRR, LCE, KRT6A, GJB2, and related genes.
- Recruitment or representation of **myeloid and inflammatory-cell programs**, including S100A8, S100A12, CXCR2, TCN1, and PLBD1.
- Additional changes in **lipid metabolism, phospholipase activity, extracellular-matrix remodeling, and cell-cycle activity**.

The dataset is highly consistent with a psoriasis lesional state, but the uploaded statistics are from a single comparison. **External statistical validation was not performed**: the evidence pack contains pathway, tissue, network, disease, and literature annotations, but no independent-cohort effect sizes or P values.

---

## 2. Core biological programs

### Program 1 — IL-36/IL-20-family inflammatory epithelial signaling

**Direction:** Strongly upregulated.

**Major supporting genes:**  
**IL36A** (+11.37), **IL36G** (+5.68), **IL36RN** (+3.01), **IL19** (+7.58), **IL20** (+5.67), **IL26** (+4.36), **TNIP3** (+7.28), **IRAK2** (+2.08), and **ZC3H12A** (+3.85).

**Relevant pathway annotations:**

- Reactome: **Interleukin-20 family signaling**.
- KEGG annotation supplied: **IL-17 signaling pathway** and **cytokine–cytokine receptor interaction**.
- GO annotations supplied for IL26 include inflammatory response, cytokine production, bacterial defense, and JAK–STAT receptor signaling.

**Interpretation:**  
Multiple cytokine ligands and pathway regulators are simultaneously induced, making this more compelling than a conclusion based on one cytokine. IL36A is the strongest effect in the table, while IL36G, IL19, IL20, and IL26 provide convergent evidence for an activated epithelial cytokine circuit. **IL36RN** is also induced, suggesting activation of an endogenous counter-regulatory response rather than unrestricted pathway activity. The direction is compatible with a lesional keratinocyte inflammatory program commonly associated with psoriasis.

**Evidence strength and limitations:**  
- **Direct dataset evidence:** Very strong, with multiple genes and extremely small FDR values.
- **Pathway evidence:** Reactome and KEGG annotations support pathway plausibility, but the supplied pathway result is not a newly computed enrichment statistic.
- **Network/regulatory evidence:** STRING records support associations involving IL26 and IL20-family receptors; these records should not be interpreted as proof of direct intracellular signaling in this tissue.
- **Literature/disease evidence:** Consistent with psoriasis biology; the supplied psoriasis literature search included an integrated biomarker study (PMID: **40560938**), but no independent expression statistic was provided.
- **Limitation:** The transcriptome cannot establish which cytokine is upstream or whether the changes are causal.

---

### Program 2 — Antimicrobial defense and innate inflammatory response

**Direction:** Strongly upregulated.

**Major supporting genes:**  
**DEFB4A** (+11.18), **DEFB4B** (+11.03), **DEFB103A** (+5.76), **DEFB103B** (+5.75), **PI3** (+9.24), **S100A7** (+7.09), **S100A7A** (+9.83), **S100A8** (+7.73), **S100A12** (+8.33), **TCN1** (+8.04), **GPR15LG** (+5.52), and **CXCR2** (+2.70).

**Relevant pathway annotations:**

- GO: **Antimicrobial humoral response**.
- GO: **Response to lipopolysaccharide**.
- KEGG annotation supplied: **Staphylococcus aureus infection**.
- KEGG annotation supplied: **IL-17 signaling pathway**.

**Interpretation:**  
The coordinated induction of several defensins, PI3, S100 proteins, and other innate-defense genes indicates a strong antimicrobial and danger-response state in lesional skin. The defensin cluster is particularly persuasive because several related genes change in the same direction, including DEFB4A/B and DEFB103A/B. S100A7/A7A and S100A8/A12 add epithelial alarmin and myeloid-inflammatory components. These changes could reflect both increased antimicrobial production by keratinocytes and increased representation of inflammatory leukocytes.

**Evidence strength and limitations:**  
- **Direct dataset evidence:** Strong and multi-gene, with large positive log2FC values.
- **Ontology/pathway evidence:** Directly supported by the supplied GO and KEGG annotations.
- **Tissue/composition evidence:** S100A8, S100A12, TCN1, and PLBD1 may indicate myeloid or granulocyte contribution, but bulk tissue data cannot determine cellular origin.
- **Limitation:** A “Staphylococcus aureus infection” annotation does not demonstrate infection of the samples; it reflects shared antimicrobial-response biology.

---

### Program 3 — Epidermal differentiation, cornified-envelope remodeling, and barrier disruption

**Direction:** Strongly upregulated.

**Major supporting genes:**  
**SPRR2A/B/D/E/F/G** (+3.99 to +7.31), **SPRR3** (+7.18), **LCE3A** (+8.30), **LCE3D** (+5.31), **KRT6A** (+4.30), **GJB2** (+4.42), **GJB6** (+3.02), **SERPINB3** (+6.74), **SERPINB4** (+9.12), **TMPRSS11D** (+7.75), **KLK13** (+4.05), and **PRSS27** (+4.24).

**Relevant pathway annotations:**

- GO: **Epidermis development**.
- Reactome: **Formation of the cornified envelope**.

**Interpretation:**  
The simultaneous increase in small proline-rich proteins, late-cornified-envelope genes, keratins, connexins, kallikrein/protease-related genes, and epithelial serpin genes is characteristic of substantial epidermal remodeling. This program likely reflects both keratinocyte differentiation abnormalities and the expanded or altered epidermal compartment in psoriatic plaques. The signal is network-like rather than dependent on one canonical marker.

**Evidence strength and limitations:**  
- **Direct dataset evidence:** Strong, with many concordant epithelial genes.
- **Pathway evidence:** GO and Reactome annotations are concordant with the gene composition.
- **Network evidence:** STRING associations among SPRR genes, KRT6A, and LCE genes support pathway/module connectivity; they do not establish direct physical interaction for every pair.
- **Limitation:** Increased expression may reflect altered cell abundance, differentiation state, or lesion thickness rather than a primary molecular defect in each gene.

---

### Program 4 — Inflammatory-cell recruitment and tissue inflammatory composition

**Direction:** Upregulated inflammatory-cell-associated signal.

**Major supporting genes:**  
**S100A8** (+7.73), **S100A12** (+8.33), **CXCR2** (+2.70), **TCN1** (+8.04), **PLBD1** (+2.08), **GPR15LG** (+5.52), **CXCL13** (+5.89), **ADAP2** (+2.09), and **TRIM15** (+4.54).

**Relevant pathway annotations:**  
The supplied GO/KEGG results include inflammatory response, response to lipopolysaccharide, cytokine interaction, and antimicrobial-response categories.

**Interpretation:**  
This pattern is compatible with increased neutrophil/granulocyte-associated activity and broader inflammatory-cell recruitment in lesional skin. S100A8/A12, TCN1, PLBD1, and CXCR2 are especially consistent with an inflammatory myeloid/granulocyte component. CXCL13 may indicate altered lymphoid-cell recruitment or organization, although its cellular source and functional role cannot be determined from this table.

**Evidence strength and limitations:**  
- **Direct dataset evidence:** Strong for the presence of an inflammatory-cell-associated transcriptional component.
- **Tissue expression evidence:** External tissue annotations provide plausibility but are not independent replication.
- **Composition limitation:** Bulk lesional skin cannot distinguish true induction within resident cells from increased abundance of infiltrating cells. This is a major alternative explanation.

---

### Program 5 — Keratinocyte metabolic, lipid, and proliferative remodeling

**Direction:** Predominantly upregulated.

**Major supporting genes:**  
**FABP5** (+3.64), **PLA2G4D** (+4.61), **PLA2G4E** (+2.47), **AKR1B10** (+6.27), **AKR1B15** (+5.23), **ABCG4** (+4.75), **KYNU** (+4.42), **WNT5A** (+2.53), **RRM2** (+2.72), and **CCNE1** (+2.56).

**Relevant pathway annotations:**

- Reactome records for **triglyceride catabolism**, **retinoic-acid signaling**, and **neutrophil degranulation** were supplied for FABP5.
- Broader pathway records include molecular-function, biological-process, and cytoplasmic modules.

**Interpretation:**  
These genes suggest altered epidermal lipid handling, inflammatory lipid mediator production, redox or carbonyl metabolism, and cell-cycle activity. RRM2 and CCNE1 are compatible with increased keratinocyte proliferation, while WNT5A may reflect altered tissue signaling. FABP5 and PLA2G4D/E provide a plausible interface between epidermal lipid biology and inflammation.

**Evidence strength and limitations:**  
- **Direct dataset evidence:** Moderate-to-strong for a coordinated metabolic/proliferative state, but weaker than for the cytokine, antimicrobial, and epidermal programs.
- **Pathway evidence:** Supports biological plausibility, not causal activity or pathway flux.
- **Therapeutic/literature evidence:** The supplied literature on AKR1B10 concerns chemoresistance in lung cancer (PMID: **39017606**), not psoriasis; it should not be used as disease-specific therapeutic validation.
- **Limitation:** Transcript abundance does not establish altered lipid flux, enzyme activity, or proliferative rate.

---

## 3. Key genes and interaction modules

The following candidates are prioritized as biologically informative modules rather than as independently validated causal targets.

1. **IL36A–IL36G–IL36RN module**  
   - **Statistics:** IL36A +11.37, IL36G +5.68, IL36RN +3.01; all FDR < 4×10⁻⁹⁰.  
   - **Role:** Central inflammatory epithelial program with simultaneous induction of agonist cytokines and the antagonist IL36RN.  
   - **Relationship type:** Cytokine pathway co-membership and regulatory signaling; not evidence of direct physical interaction among the encoded proteins.  
   - **Priority:** Highest for mechanistic follow-up because of large effects and coherent pathway structure.

2. **IL19–IL20–IL26 inflammatory cytokine module**  
   - **Statistics:** IL19 +7.58, IL20 +5.67, IL26 +4.36.  
   - **Role:** Interleukin-20-family and epithelial JAK–STAT-associated signaling.  
   - **Relationship type:** Pathway co-membership and putative cytokine–receptor signaling. STRING records for IL26 include IL10RB, IL20RA, IL20RB, IL22RA1, and IL19, but STRING association is not equivalent to demonstrated direct physical interaction in these samples.

3. **DEFB4A/B–DEFB103A/B antimicrobial module**  
   - **Statistics:** DEFB4A +11.18, DEFB4B +11.03, DEFB103A +5.76, DEFB103B +5.75.  
   - **Role:** Antimicrobial epithelial defense and IL-17-linked lesion response.  
   - **Relationship type:** Gene-family/pathway co-membership and likely co-regulation; direct protein interaction is not established by the supplied evidence.

4. **S100A7–S100A7A–S100A8–S100A12 module**  
   - **Statistics:** S100A7 +7.09, S100A7A +9.83, S100A8 +7.73, S100A12 +8.33.  
   - **Role:** Epithelial alarmin, antimicrobial, and myeloid-inflammatory signaling.  
   - **Relationship type:** Co-expression and inflammatory-program co-membership. STRING provides associations involving S100A7, FABP5, S100A12, S100A7A, SERPINB3, and SERPINB4, but this does not prove direct physical interaction for all edges.

5. **SPRR–LCE–KRT6A epidermal remodeling module**  
   - **Statistics:** Multiple SPRR genes are upregulated, including SPRR2A +7.31, SPRR3 +7.18, SPRR2F +7.22, LCE3A +8.30, LCE3D +5.31, and KRT6A +4.30.  
   - **Role:** Cornified-envelope formation, keratinocyte differentiation, and barrier remodeling.  
   - **Relationship type:** Reactome pathway co-membership and STRING network association; some proteins may physically associate, but the supplied records do not establish a direct physical interaction for every listed pair.

6. **SERPINB3–SERPINB4–PI3 protease/barrier module**  
   - **Statistics:** SERPINB3 +6.74, SERPINB4 +9.12, PI3 +9.24.  
   - **Role:** Epithelial protease inhibition, barrier biology, and inflammatory tissue remodeling.  
   - **Relationship type:** Functional/pathway relationship and possible indirect protease-network interaction; direct physical interaction is insufficiently documented here.

7. **FABP5–PLA2G4D/PLA2G4E lipid-inflammatory module**  
   - **Statistics:** FABP5 +3.64, PLA2G4D +4.61, PLA2G4E +2.47.  
   - **Role:** Lipid handling and potential generation or regulation of inflammatory lipid mediators.  
   - **Relationship type:** Metabolic pathway co-membership and putative functional relationship. STRING reports FABP5 associations with PPARD, PPARG, FAAH, and S100A7; these are database-derived associations, not proof of direct physical binding in lesional skin.

8. **CXCL13–CXCR2–GPR15LG inflammatory recruitment module**  
   - **Statistics:** CXCL13 +5.89, CXCR2 +2.70, GPR15LG +5.52.  
   - **Role:** Candidate chemotactic and immune-recruitment program.  
   - **Relationship type:** Indirect chemokine/receptor or tissue-recruitment relationship; the transcript data do not demonstrate ligand–receptor activity or cell-to-cell directionality.

9. **RRM2–CCNE1 proliferative module**  
   - **Statistics:** RRM2 +2.72 and CCNE1 +2.56.  
   - **Role:** Compatible with increased keratinocyte cell-cycle activity in lesional epidermis.  
   - **Relationship type:** Functional cell-cycle co-membership, not a demonstrated direct interaction in this dataset.

10. **CD274 inflammatory immune-regulatory signal**  
    - **Statistics:** CD274 +3.44, FDR 1.82×10⁻⁶³.  
    - **Role:** May reflect inflammatory induction of PD-L1 in keratinocytes or infiltrating immune/stromal cells.  
    - **Relationship type:** Immune-regulatory pathway association. Therapeutic literature exists for CD274-directed approaches in other contexts, including PMID: **38354028**, but this does not establish efficacy in psoriasis or justify CD274 as a therapeutic target here.

---

## 4. Validation priorities

### 1. Test IL-36/IL-20-family signaling in lesional keratinocytes  
**Class:** Mechanistic hypothesis  
**Current evidence:** IL36A, IL36G, IL19, IL20, and IL26 are strongly upregulated, with IL36A reaching log2FC 11.37; IL36RN is also increased.  
**External support:** Reactome IL-20-family annotations and GO JAK–STAT/inflammatory annotations support plausibility; these are contextual rather than independent cohort validation.  
**Next step:** Perform paired lesional/nonlesional or normal-skin validation by qPCR, RNA in situ hybridization, immunohistochemistry, and protein-level cytokine assays. In primary keratinocytes or organotypic skin, perturb IL-36 signaling and measure defensins, SPRR/LCE genes, and inflammatory cytokines.  
**Conclusion:** **Supported hypothesis**, not established causality.

### 2. Validate the antimicrobial–barrier signature as a lesional-skin biomarker  
**Class:** Biomarker  
**Current evidence:** Coordinated induction of DEFB4A/B, DEFB103A/B, PI3, S100A7/A7A, SPRR, and LCE genes, all with very small FDR values.  
**External support:** Supplied GO terms for antimicrobial humoral response and epidermis development, plus psoriasis-related literature retrieval including PMID **40560938**, support biological relevance. No independent diagnostic performance statistic was supplied.  
**Next step:** Test a compact multi-gene or protein panel in an independent psoriasis cohort, including nonlesional skin and inflammatory dermatosis controls, and evaluate association with clinical severity and treatment response.  
**Conclusion:** **Supported hypothesis**; clinical utility remains **insufficient evidence**.

### 3. Separate keratinocyte induction from inflammatory-cell composition  
**Class:** Confounding or composition check  
**Current evidence:** Strong epithelial genes coexist with S100A8, S100A12, TCN1, PLBD1, CXCR2, and other inflammatory-cell-associated signals.  
**External support:** Tissue-expression and disease annotations support plausible cellular assignments, but they do not identify the source in these samples.  
**Next step:** Use single-cell or spatial transcriptomics, cell deconvolution with validated reference profiles, and immunostaining for keratinocytes, neutrophils, monocytes, and lymphocytes. Laser-capture microdissection or sorted-cell RNA-seq would provide an additional distinction.  
**Conclusion:** This is an essential **confounding/composition check**; the bulk data alone provide **insufficient evidence** to assign every gene to a specific cell type.

### 4. Test the FABP5–PLA2G4D/E lipid-inflammatory axis  
**Class:** Mechanistic hypothesis  
**Current evidence:** FABP5, PLA2G4D, and PLA2G4E are all upregulated, with log2FC values of +3.64, +4.61, and +2.47, respectively.  
**External support:** Reactome annotations link FABP5 to lipid metabolism and retinoic-acid signaling; STRING provides associations with PPARD, PPARG, FAAH, and S100A7. The AKR1B10 literature record (PMID **39017606**) is cancer-focused and does not validate this mechanism in psoriasis.  
**Next step:** Measure lipid mediator profiles in matched lesional/nonlesional tissue, assess enzyme activity, and perturb FABP5 or PLA2G4D/E in keratinocyte cultures or organotypic models.  
**Conclusion:** **Exploratory to supported hypothesis**, depending on biochemical confirmation.

### 5. Evaluate the SPRR/LCE/KRT6A epithelial remodeling network  
**Class:** Interaction / network hypothesis  
**Current evidence:** Numerous SPRR and LCE genes, KRT6A, GJB2, GJB6, KLK13, and protease-associated genes are concordantly upregulated.  
**External support:** Reactome cornified-envelope annotations and STRING associations support network-level organization. These associations may represent pathway co-membership, co-expression, or predicted functional links rather than direct physical interactions.  
**Next step:** Validate spatial co-localization and protein expression, then perturb selected regulators in keratinocyte differentiation models and measure barrier function, transepithelial resistance, and cornified-envelope formation.  
**Conclusion:** **Supported hypothesis** for coordinated remodeling; causal hierarchy is **insufficient evidence**.

---

## 5. Evidence grounding and conflicts

- **Direct input evidence:** The strongest evidence is the supplied differential-expression result. All 100 genes have FDR ≤ 0.01; 90 are upregulated and 10 are downregulated. The downregulated genes include **LOC107984452** (log2FC −6.25), **BTC** (−4.30), **CYP2W1** (−4.70), **WAKMAR1** (−5.63), **SAPCD1** (−2.94), and **UGT3A2** (−4.59). These changes should be preserved as part of the lesion-versus-control contrast, but their functions are less coherent in the supplied evidence than the dominant upregulated programs.
- **Pathway/ontology evidence:** The supplied GO, Reactome, and KEGG annotations converge on epidermis development, cornified-envelope formation, antimicrobial response, IL-17 signaling, cytokine interaction, and bacterial-defense categories. These are annotations to the selected genes, not newly calculated enrichment statistics in this answer.
- **Network evidence:** STRING, OmniPath, TRRUST, and related records provide contextual relationship information. The records are not automatically independent and may share literature or prediction sources.
- **Disease and tissue evidence:** GWAS, tissue-expression, disease-association, and protein-annotation records support plausibility but do not constitute replication of the uploaded effect sizes.
- **Literature evidence:** The supplied literature search returned psoriasis-related biomarker work, including PMID **40560938**, and broader mechanistic or therapeutic records. However, the retrieved records do not provide an independent cohort statistic matching this exact comparison. Therefore, **external statistical validation was not performed**.
- **Therapeutic evidence:** Drug or clinical-trial records exist for some genes, including CD274 and AKR1B10-related records, but drug availability is not evidence that the corresponding target is effective for psoriasis.

No major contradiction is evident among the dominant programs. The principal uncertainty is not biological direction but whether the bulk-tissue signal reflects cell-intrinsic activation, altered cellular composition, or both.

---

## 6. Limitations and alternative explanations

1. **Cellular composition and lesion architecture**  
   The mixture of strong epithelial and myeloid-associated signals may reflect thicker epidermis and inflammatory-cell infiltration. Single-cell/spatial profiling and cell-type-specific staining are needed to distinguish composition from within-cell induction.

2. **Disease severity, treatment, and clinical heterogeneity**  
   Lesional skin may differ in severity, chronicity, anatomical site, or treatment exposure. These variables can alter cytokine, barrier, and proliferation programs. Matched metadata and paired lesional/nonlesional sampling are important.

3. **Bulk transcript abundance versus pathway activity**  
   mRNA changes do not prove cytokine secretion, receptor activation, lipid mediator production, enzyme activity, or functional barrier failure. Protein assays, phospho-signaling measurements, lipidomics, and functional epidermal assays are required.

4. **Association-versus-causation ambiguity**  
   The results identify a reproducible molecular state within this comparison but cannot establish that IL36A, S100A7, DEFB4A/B, FABP5, or any other gene initiates psoriasis. Perturbation experiments and longitudinal treatment-response studies are required.

5. **External validation is absent**  
   The extreme P values and FDR values demonstrate strong statistical separation in the supplied dataset, but no independent-cohort statistics were provided. The pathway recurrence and literature support should therefore be treated as plausibility and prioritization evidence, not replication or clinical validation.

Overall, the most defensible interpretation is that psoriatic lesional skin exhibits a coordinated **IL-36/IL-20-family inflammatory, antimicrobial, epidermal-remodeling, and inflammatory-cell-associated state**, with lipid and proliferative remodeling as secondary programs; the causal hierarchy and clinical utility of individual genes remain to be experimentally established.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=4, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
